EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Application of intrathecal trastuzumab for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer



Application of intrathecal trastuzumab for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer



Journal of Clinical Oncology 26(15_suppl): 1138-1138



NlmCategory="UNASSIGNED">1138 Background: When the humanized anti-HER2 monoclonal antibody trastuzumab is given intravenously, very little reaches the cerebrospinal fluid (CSF). Thus, carcinomatous meningitis may occur in patients with complete systemic remission induced by trastuzumab therapy. Intracerebral injections in rats with meningeal carcinomatosis have shown an increase in survival without clinical or histologic toxic effects. Three cases of meningeal dissemination from breast cancer treated with intrathecally administered trastuzumab have been reported clinically without any significant adverse events. Here we report a case of a 66-year-old woman with HER2-overexpressing metastatic breast cancer who suffered from meningeal carcinomatosis and was treated with intrathecal trastuzumab. The patient developed invasive apocrine carcinomas (six involved nodes, hormone receptor-negative and HER2 3+) in her right breast and was initially treated with mastectomy and axillary nodal dissection followed by chemotherapy (CEF; cyclophosphamide, doxorubicine, and 5-fluorouracil followed by docetaxel) and radiotherapy (50 Gy). Two years later, the patient had episodes of vertigo and headaches. MRI and CSF analysis indicated brain metastasis and meningeal carcinomatosis without any metastatic lesions other than these metastatic sites. An Ommaya reservoir for intrathecal treatment with methotrexate and cytarabine was placed surgically, and the patient was treated with intrathecal chemotherapy and whole-brain radiotherapy (40Gy). Meningeal enhancement and brain tumor on MRI and tumor cell counts in CSF still remained after the maximal treatment cycle. As the next choice of treatment, intrathecal therapy with weekly trastuzumab (25 mg/body) was begun after approval of IRB. After 6 injections of trastuzumab, malignant cells in CSF disappeared and interestingly the brain tumor shrank. The patient still continues intrathecal trastuzumab without any clinical toxic effects. Considering the few options for treatment of meningeal dissemination in MBC, this approach might be a viable method of treatment for meningeal dissemination of HER2-positive MBC patients through appropriate clinical trials. No significant financial relationships to disclose.

(PDF emailed within 1 workday: $29.90)

Accession: 057223024

Download citation: RISBibTeXText

PMID: 27950838



Related references

Application of intrathecal trastuzumab (Herceptin (TM)) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncology Reports 15(5): 1373-1377, 2006

Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncology Reports 15(5): 1373-1377, 2006

Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anti-Cancer Drugs 19(8): 832-836, 2008

Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Research and Treatment 139(1): 13-22, 2013

Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet. Oncology 7(9): 778-780, 2006

Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62(1): 209-243, 2002

Treatment of HER2 overexpressing metastatic breast cancer with trastuzumab and chemotherapy. Breast Cancer Research & Treatment 64(1): 123, November, 2000

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet. Oncology 17(3): 357-366, 2016

Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer. Clinical Breast Cancer 9(3): 178-183, 2009

Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer. Breast Care 9(5): 344-348, 2015

Trastuzumab plus GM-CSF for patients with trastuzumab-resistant, HER2-overexpressing metastatic breast cancer: Pilot study. Journal of Clinical Oncology 23(16_suppl): 803-803, 2016

Oral and intravenous vinorelbine plus trastuzumab for 1st-line treatment of HER2-overexpressing metastatic breast cancer (MBC). A trial of the german AIO breast cancer group. Journal of Clinical Oncology 26(15_suppl): 1061-1061, 2016

Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer. Drugs 69(15): 2125-2148, 2010

Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Research and Treatment 127(3): 841-844, 2011

Trastuzumab's association with cerebral metastases and meningeal carcinomatosis in a patient with HER2-positive breast cancer. Medicina Clinica 133(7): 279-280, 2009